EXHIBIT 10.4
ANIKA RESEARCH, INC.
▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
April 29, 1993
MedChem Products, Inc.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, President
and Chief Executive Officer
Gentlemen:
This letter agreement is being sent to you to confirm our understanding
regarding payments to be made by Anika Research, Inc. ("Anika") to MedChem
Products, Inc. ("MedChem") in connection with the commercial sale of Anika's
hyaluronic acid ("HA") product called ORTHOVISC(TM) for the non-surgical
treatment of temporomandibular joint dysfunction ("TMJ Products"). In
consideration of MedChem's prior investment in the development of TMJ Products,
Anika has agreed to make the following payments ("Payments"), subject to the
limitations below, to MedChem:
(a) Payments will equal three percent (3%) of the Net Sales (as
defined below) of TMJ Products by Anika during a period: beginning on the
date of the first commercial sale of TMJ Products and ending on February
27, 1996; and
(b) Payments will equal twelve percent (12%) of the Net Sales of TMJ
Products by Anika following February 27, 1996.
The Payments will be made to MedChem on January 15, April 15, July 15 and
October 15 of each year until Anika's obligation to make such Payments expires
in accordance with this agreement. Concurrently with each Payment, Anika will
provide to MedChem the number of units of TMJ Products sold by Anika during the
preceding fiscal quarter of MedChem (or part thereof).
Anika will keep separate, true and accurate books and records respecting
all transactions related to this agreement in accordance with generally accepted
accounting practices consistently applied, which books and records shall be kept
and maintained so as to permit verification of the payments due MedChem under
this agreement. Anika shall maintain such books and records for a period of at
least three (3) years following the close of the fiscal year in which they
pertain.
For purposes of determining the Payments to be made to . MedChem, "Net
Sales" shall mean Anika's aggregate gross invoice price from or on account of
the sale of TMJ Products, less: (i) trade and quantity discounts actually
allowed; (ii) returns, rebates and allowances
actually allowed; (iii) transportation, shipping and insurance charges
separately stated on the invoice and paid by the customer; and (iv) sales and
excise taxes, foreign tariffs and duties.
The Payments will be made to MedChem on all commercial sales of TMJ
Products following the grant by the U.S. Food and Drug Administration of a
pre-market approval for TMJ Products and shall continue until the earlier to
occur of (i) ten (10) years following the first commercial sale of TMJ Products
by Anika, and (ii) such time as Anika has made Payments to MedChem under this
agreement totalling $35 million. Furthermore, Anika's obligation to make
Payments to MedChem will cease if Anika appoints MedChem to be Anika's exclusive
distributor of TMJ Products in the United States. This agreement should not be
construed as an agreement or commitment by Anika to appoint MedChem as Anika's
exclusive distributor of TMJ Products.
In the event that Anika reasonably believes that its obligation to make
the Payments under this agreement is materially impairing its ability to
effectively market and sell TMJ Products, Anika and MedChem agree to renegotiate
the terms of this agreement in good faith, provided that MedChem is under no
obligation to alter the amount or timing of the Payments.
If this agreement is satisfactory to you, I would ask that you execute a
copy of this letter and return it to me.
Sincerely yours,
ANIKA RESEARCH, INC.
By:/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
Chairman of the Board,
President and Chief Executive Officer
Agreed to and
Accepted this 29th
day of April, 1993:
MEDCHEM PRODUCTS, INC.
By: /s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
President and Chief
Executive Officer